Advertisement

Topics

Sobi Inc. Company Profile

04:43 EST 13th December 2018 | BioPortfolio


News Articles [76 Associated News Articles listed on BioPortfolio]

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orp...

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ continues sell-off, SOBI spies US expansion

AstraZeneca Sells Synagis Rights to Sobi

Anglo-Swedish drugmaker AstraZeneca has sold US right for its Synagis infant respiratory drug to Swedish Orphan Biovitrum (Sobi) for an upfront sum of $1.5 billion. The payment consists of $1 billion ...

Sobi gains exclusive US rights to AZ's Synagis; deal value tops $2.3bn

AstraZeneca PLC sold Swedish Orphan Biovitrum AB (Sobi) exclusive rights to commercialize the respiratory syncytial virus therapy Synagis (palivizumab) in the US. Sobi will also participate in AZ’s ...

Sobi's Recently Acquired Gamifant Gets FDA Approval for Ultra-Rare Disease

Sweden-based Sobi and Swiss-based Novimmune announced the U.S. approval of Gamifant (emapalumab-lzsg) to treat an ultra-rare disease in adults and children. Sobi’s U.S. offices are in Waltham, Mass.

Sobi's Recently-Acquired Gamifant Gets FDA Approval for Ultra-Rare Disease

Sweden-based Sobi and Swiss-based Novimmune announced the U.S. approval of Gamifant (emapalumab-lzsg) to treat an ultra-rare disease in adults and children. Sobi’s U.S. offices are in Waltham, Mass.

AstraZeneca sells lung med to Sobi for $1.5 billlion

The company will gain an 8 percent ownership stake in Sobi with the deal's total value reaching $2.3 billion when including deferred and contingency payments

AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn

AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory syncytial virus (RSV), to Swedish rare di...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [6 Associated Companies listed on BioPortfolio]

Swedish Orphan Biovitrum AB

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families. Sobi have a diversi...

Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the li...

Sobi Inc.

Biogen and Sobi

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare ...

Bioverativ Inc. & Sobi

Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class re...

More Information about "Sobi Inc." on BioPortfolio

We have published hundreds of Sobi Inc. news stories on BioPortfolio along with dozens of Sobi Inc. Clinical Trials and PubMed Articles about Sobi Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sobi Inc. Companies in our database. You can also find out about relevant Sobi Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record